Case Study: TargetCancer Foundation expands access and empowers rare cancer patients with Medrio's remote eConsent

TargetCancer Foundation Successfully Engages and Empowers Rare Cancer Patients with Medrio

TargetCancer Foundation, a patient‑founded nonprofit, ran the TCF‑001 TRACK study to determine whether patients with rare tumors can benefit from matched molecular therapy and needed a way to consent and engage a geographically dispersed cohort of 400 U.S. patients. They faced challenges around patient access without travel, ensuring patient/caregiver understanding of complex genomic information, and lack of real‑time visibility into the consent process, so they implemented Medrio’s remote consent/eConsent capability within Medrio’s eClinical platform.

Medrio provided an intuitive, configurable remote informed consent solution with 24/7 support that allowed same‑day changes and real‑time tracking of consent delivery and receipt. As a result, TargetCancer Foundation removed geographic barriers, empowered patients and caregivers to initiate and review consent from home, increased patient questions and comprehension, eliminated mail delays, and gained always‑on visibility into consent status while continuing to enroll and manage the 400‑patient study with Medrio’s support.

TargetCancer Foundation

Jim Palma

Executive Director